Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells
- PMID: 1867955
- DOI: 10.3727/095535491820873236
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells
Abstract
Recombinant human interferon-alpha 2a (rIFN-alpha 2a; 500 or 5,000 IU/mL) or [6RS] leucovorin ([6RS]LV; 1 microM) each potentiated the cytotoxic activity of 5-fluorouracil (FUra) by 2.6- to 3.2-fold during 72 hr exposures in two human colon adenocarcinoma cell lines (GC3/c1; VRC5/c1). When all three agents were combined, FUra cytotoxicity was further potentiated by 3.2- to 4.3-fold (total 10- to 14-fold). Potentiation of FUra cytotoxicity occurred at clinically achieveable concentrations of rIFN-alpha 2a and [6RS]LV. Effects were reversed by dThd (20 microM), although the activity of CB3717, a quinazoline-based, specific inhibitor of thymidylate synthase, was not potentiated by rIFN-alpha 2a. Data suggest the requirement of a 5-fluoropyrimidine for biochemical modulation and interaction at the level of thymidylate synthase or DNA.
Similar articles
-
Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.Cancer Res. 1993 Sep 15;53(18):4243-50. Cancer Res. 1993. PMID: 8364921
-
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.Cancer Res. 1990 Jul 1;50(13):3940-6. Cancer Res. 1990. PMID: 2354443
-
A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.Clin Cancer Res. 1999 Feb;5(2):425-30. Clin Cancer Res. 1999. PMID: 10037193
-
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.Cancer. 1989 Mar 15;63(6 Suppl):1008-12. doi: 10.1002/1097-0142(19890315)63:6+<1008::aid-cncr2820631303>3.0.co;2-z. Cancer. 1989. PMID: 2521810 Review.
-
The role of interferon-alpha as a modulator of fluorouracil and leucovorin.Eur J Cancer. 1995 Jul-Aug;31A(7-8):1316-20. doi: 10.1016/0959-8049(95)91267-g. Eur J Cancer. 1995. PMID: 7577043 Review.
Cited by
-
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.Med Oncol. 1995 Mar;12(1):3-8. doi: 10.1007/BF01571402. Med Oncol. 1995. PMID: 8542244 Review. No abstract available.
-
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.Pharm World Sci. 1994 Apr 15;16(2):84-103. doi: 10.1007/BF01880660. Pharm World Sci. 1994. PMID: 7518280 Review.
-
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.Cancer Chemother Pharmacol. 1993;32(5):347-52. doi: 10.1007/BF00735917. Cancer Chemother Pharmacol. 1993. PMID: 8339384 Clinical Trial.
-
Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.Cancer Chemother Pharmacol. 1994;35(1):21-30. doi: 10.1007/BF00686280. Cancer Chemother Pharmacol. 1994. PMID: 7527304 Review.
-
Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.Br J Cancer. 1994 Oct;70(4):724-8. doi: 10.1038/bjc.1994.383. Br J Cancer. 1994. PMID: 7917928 Free PMC article. Clinical Trial.